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INTRODUCTION
The process of cancer progression consists ofmultisteps,
which can be rate limiting since a failure or an in-
sufficiency at any of the steps aborts the process
(1-3). The outcome of the process is dependent on both
the intrinsic properties of the tumor cells and the re-
sponses of the host. The steps or events required
for the formation of tumor invasion and metastasis
are the same in all tumors (Fig. 1). The major steps
in tumor progression are as follows : 1) After the ini-
tial transformation, tumor cells grow at the primary
site. 2) Neovascularization must occur when the tumor
mass forms 2 mm more in diameter (4). Several angiogenic
factors play key roles to establish neovascularization
(5-7). 3) Local invasion of the basement membrane
and degradation of the stroma are necessary formigration
from the primary site (8 -11). Matrix metalloproteinases
may play the most important role in these steps. 4)
Thin-walled venules, like lymphatic channels or small
capillaries, must be penetrated by tumor cells for tumor
cell entry into the circulation. Some carcinomas me-
tastasize and grow via the lymphatic system, and
others spread via the hematogeneous route. 5) After
the circulating tumor cells attach to the epithelium
of venules, extravasation occurs via a similar mecha-
nism as the initial invasion. 6) Tumor cells grow at
distant sites with neovascularization, similar to pri-
mary site, and metastatic tumors can be established.
Then the metastatic process can be completed. To
produce detectable lesions, the metastases must de-
velop neovascularization, evade the host immune
system (12), and respond to organ-specific factors
that influence their growth (13-17). Many factors have
essential roles in this metastatic process, and thema-
trix metalloproteinases (MMPs) must be one of the
most important factors in several steps.
MATRIX METALLOPROTEINASES (MMPs) : STRUC-
TURE, FUNCTION AND REGULATION
In many physiological states or processes, degra-
dation of extracellular matrix is very important and
essential, for example, during development, growth,
and repair or remodeling of organ tissues (18-21).
However, excessive degradation of tissues or proteolysis
causes several pathological conditions, for example,
rheumatoid arthritis, osteoarthritis, autoimmune dis-
orders of skin, and others (18, 22, 23). In addition, in
tumor invasion, metastasis and angiogenesis, degradation
of the extracellular matrix is an essential steps and
increased expression levels of matrix metalloproteinases
(MMPs) is associated with tumor invasion and me-
tastasis with different histogenetic origin (19, 24).
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(1) Structure
MMPs are a family of at least 20 human zinc-dependent
endopeptidases, which, collectively capable of degrad-
ing extracellular matrix components (19, 22, 23, 25 -27).
These members of the MMP gene family can be
classified into subgroups of collagenases, stromelysins,
gelatinases, membrane-type MMPs, and other MMPs
according to their substrate specificity and structure
(Table 1). In general,MMPs contain a signal/propeptide
domain, a catalytic domain with the highly conserved
zinc binding site, hinge region, and a hemopexin-like
domain (Fig. 2). In addition, gelatinase-A (MMP-2)
and gelatinase-B (MMP-9) contain a gelatin-binding
site as fibronectin type II inserts within the catalytic
domain, and MT-MMPs contain a transmembrane
domain in the c-terminal of the hemopexin-like do-
main. A hemopexin-like domain is absent inmatrilysin
(MMP-7), the smallest MMP (18, 27). The substrate
specificity of MMPs has been determined by their
ability to degrade different components of extracellular
matrix in vitro, however, no direct evidence was ob-
tained in vivo .
(2) Function
Collagenase, including interstitial collagenase (MMP-1),
neutrophil collagenase (MMP-8), and collagenase-3
(MMP-13) are the secreted neutral proteinases ca-
pable of degradation of native fibrillar collagens of types
I, II, III (18, 23). These collagenases play a crucial
role in degradation of collagenous extracellular matrix
in various physiological and pathological situations (28-
30). Gelatinase-A (MMP-2, 72 kDaType IV collagenase)
is expressed by a variety of normal and transformed
cells. Gelatinase-B (MMP-9, 92 kDaType IV collagenase)
is produced by monocytes, alveolar macrophages, and
various malignant cells (18, 23). In addition, MMP-2
and MMP-9 can degrade gelatin, laminin, and MMP-2
has also been reported to degrade native type I col-
lagen and activate MMP-9 and MMP-13 (24, 31). The
stromelysin subgroup contains stromelysin-1 (MMP-3),
stromelysin-2 (MMP-10), and stromelysin-3 (MMP-11)
(18, 23). MMP-3 and MMP-10 are expressed by
fibroblastic cells and by normal and transformed
squamous epithelial cells (28, 30). Stromelysins degrade
basement membrane components, type IV collagen,
and fibronectin (18, 23). The cDNA of stromelysin-3
(MMP-11) was cloned from invasive breast cancer
tissue (32). The predicted structure of MMP-11 re-
sembles that of other stromelysins and collagenases
(18, 23). The smallestMMP-7,matrilysin can degrade
gelatin I, III, IV, V and some other extracellular ma-
trix including fibronectin. Moreover, both matrilysin
and macrophage metalloelastase have the ability to
degrade elastin (18, 22, 23). The first membrane-type
MMP (MT 1-MMP, MMP-14) was cloned from in-
vasive lung cancer cells (33) and revealed a typical
Fig. 1. Multisteps of tumor invasion and metastasis. Tumor cells must complete a series of sequential steps for production of me-
tastasis. Many factors are associated with these process, for example, MMPs, angiogenic factors, and adhesion molecules. MMPs
have essential roles in these multisteps.
H. Kanayama. Matrix metalloproteinases and bladder cancer３２
five-domain modular structure resembling collagenases
and stromelysins;it also contains an additional short
carboxyl-terminal transmembrane domain. Three other
MT-MMPs ; MT2-MMP (MMP-15),MT3-MMP (MMP-16),
and MT4-MMP (MMP-17)were cloned. ActiveMT1-MMP
serves as a cell membrane receptor for the complex
formed of latent MMP-2 (proMMP-2) and tissue
inhibitor of metalloproteinases-2 (TIMP-2). The com-
plex of MT1-MMP and MT2-MMP works at the cell
surface as an activator for proMMP-2.
Most MMPs are secreted as latent proenzyme that
are proteolytically activated in the extracellular space,
with the exception ofMMP-11 andMT1-MMP, which
are activated prior to secretion intracellularly by
furin-like proteases (18, 22, 23, 31). The activity of
MMPs in the extracellular space is specifically in-
hibited by tissue inhibitors of metalloproteinases
(TIMPs), which bind to the highly conserved zinc
binding site of active MMPs at molar equivalence. The
TIMP gene family consists of four structurally related
members, TIMP-1, -2, -3, and -4, which show 30 to 40%
identity at the amino acid level and possess 12 con-
served cysteine residues (34). TIMP-1, -2, and -4 are
secreted in soluble form whereas TIMP-3 is associ-
ated with extracellular matrix. TIMPs have biological
effects that extend beyond their role as inhibitors
of MMP activity (35). They induce changes in cell
morphology, stimulate growth of several cell types,
and TIMP-2 is also involved in activation of MMP-2
(31).
(3) Regulation
Regulation of the MMPs is exerted at many levels
and involves both transcriptional and post-transcriptional
Table 1. MMP and TIMP family
MMP group and TIMP MMP Name(Enzyme)
Molecular weight
Substrates
Latent Active
Collagenases
1 Interstitial collagenase 55000 45000 Fibrillary collagens I, II, III, VI, IX,
Proteoglycans
8
13
Neutrophil collagenase
Collagenase 3
75000
60000
58000
48000
Collagen type I, II, III
Collagen type I, II, III
Gelatinases
2 Gelatinase A
72 kD Gelatinase
72 kD Type IV collagenase
72000 66000 Gelatin type I, II, III, Collagen type IV,
V, VII, X, Fibronectin, Elastin
9 Gelatinase B
92 kD Gelatinase
92 kD Type IV collagenase
92000 86000 Gelatin type I, V, Collagen type IV, V
Stromelysins
3 Stromelysin-1
Procollagenase
57000 45000 Cartilage proteoglycans , Fibronectin ,
Laminin, Gelatin type I, III, IV, V, Collagen
type III, IV, V, IX, Procollagenase
10 Stromelysin-2 57000 44000 Gelatin type I, III, IV, V, Collagen III,
IV, V, Procollagenase, Fibronectin
11 Stromelysin-3 51000 44000 Casein
Membrane-type MMPs
14 MT1-MMP 66000 56000 ProMMP-2, Collagen I, II, III, Gelatin,
ProTNF
15
16
17
MT2-MMP
MT3-MMP
MT4-MMP
72000
64000 52000
ProMMP-2
ProMMP-2
Others
7 Matrilysin or PUMP-1 28000 19000 Gelatin I, III, IV, V, Cartilage Proteoglycan,
Fibronectin, Procollagenase, ProTNF, Collagen IV
12 Macrophage metalloelastase 54000 45000/22000 Elastin
Tissue inhibitors of MMPs
TIMP-1 28500(glycosylated) All MMPs except MMP-14, MMP-19,
Binds to ProMMP-9
TIMP-2 21000(unglycosylated) All MMPs, Binds to ProMMP-2
TIMP-3 27000(glycosylated) All MMPs, Binds to ProMMP-2 and ProMMP-9
24000(unglycosylated)
TIMP-4 23000(unglycosylated) MMP-1, 2, 3, 7, 9, Binds to ProMMP-2
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mechanisms (25, 36). Many different factors have
been shown to influence the transcription of MMPs,
including hormones, growth factors, oncogenes, and
cytokines (19, 37, 38). The mechanism of transcriptional
activation has been extensively studied and the AP-1
binding site has been the focus of much recent re-
search (36). The AP-1 binding site is located upstream
from the transcriptional activation site and has been
considered to play an important role in the transcriptional
activation of the MMP promoters. From a recent
study, the interaction of this site with other cis-acting
elements is necessary for basal transcription and in-
duction by cytokines and growth factors (39, 40).
The AP-1 site is also involved in the down-regulation
of MMPs by transforming growth factor beta, retinoids
and glucocorticoids. Several findings suggested that
the MMP subgroup was independently regulated
(41, 42). In a recent study, a single nucleotide poly-
morphism in the MMP-1 promoter increased the
transcription rate of the MMP-1 gene (43). The in-
creased frequency of the GG polymorphism in several
tumor-derived cell lines may be associated with in-
creased matrix degradation (43). The solubleMMPs,
such as collagenases, gelatinases, and stromelysins,
are secreted as proenzymes, requiring activation.
Acquisition of proteolytic activity is associated with the
loss of the amino-terminal pro-domain (18, 23). It
is becoming apparent that the MMPs interact with
other proteases, for example, plasmin andMT1-MMP (44).
THE ROLE OF MMPs IN TUMOR INVA-
SION AND METASTASIS
(1) MMPs expression in malignant tumors
Liotta et al. described the role of MMPs in cancer
in 1980 (45). They identified a type IV collagenase
involved in melanoma invasion and metastasis, and
suggested that proteolysis was essential step in tumor
invasion. From the cloning of the type IV collagenase,
this activity has been considered to be attributed to
MMP-2 or MMP-9 (46, 47). Although it was initially
suggested that the tumor cells produced these MMPs,
it has become clear that the interaction between host
stromal cells and tumor cells was important for the
induction of MMPs (48). The concept of stromal cell
expression of MMPs has been acceptable by the iden-
tification of stromelysin-3 as a stromal metalloproteinase
associated with breast cancer (32). In situ hybridization
for MMP revealed that the expression of MMPs in
stromal cell is more common than in tumor cells.
Many MMPs are induced in connective tissue cells,
including fibroblasts and inflammatory cells. There
is some evidence that the mRNA of MMP-2 is pro-
duced by stroma cells, but the protein is located in
tumor cells, especially in the invasive front of tumor
Fig. 2. The structure of MMPs. MMPs consist of the N-terminal signal/propeptide, catalytic, hinge, and C-terminal hemopexin do-
mains. Gelatinases include the gelatin-binding domain, MMP-7 lacks the hemopexin domain, and MT-MMP has transmembrane do-
main. ProMMPs can be activated by cleavage of the propeptide domain which includes PRCGVPD.
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tissue (49). In addition, matrilysin is commonly ex-
pressed in the epithelial component of adenocarcinomas
(50).
There is a general correlation between the stage
of tumor progression and the level of MMPs expres-
sion (26, 27). In a murine system of squamous cell
carcinomas, high levels of stromelysin-1 in highly
metastatic spindle-cell carcinomas and very low levels
in benign papillomas were observed (51). The expres-
sion of MMP-9 is associated with melanoma growth
and subsequent metastasis (52), and high expression
of MMP-2 is associated with high tumor grade (53).
MMP-2 is widely expressed in breast cancers, however,
the ratio of the active form of MMP-2 is increased
in advanced disease. In addition, malignant tumors
tend to express various MMPs rather than benign
tissues (54, 55). Colon adenocarcinomas express
matrilysin, stromelysin-1, stromelysin-3, MMP-2, and
collagenase-1 (56). From these findings, there is a
general positive correlation between tumor aggres-
siveness and the expression of MMPs.
The ability of the diagnostic or prognostic value
of the expression of the MMPs or TIMPs were ob-
served in some studies (26). Expression of stromelysin-3
has been associated only in malignant breast tumors,
and it is not expressed in benign tissues (57). Al-
though some other studies have reported associa-
tions between stromelysin-3 expression and lymph
node metastasis, and, thus, shorter survival in patients
with infiltrating ductal carcinoma of the breast, larger
studies are necessary to clarify the true value (58-
61). In addition, high levels of serum MMP-2 were
observed in the patients with prostate cancer (62).
Another study mentioned that tissue levels of active
MMP-2 were associated with Gleason score and lymph
node metastases, and high levels of serum MMP-2
were also found in patients with prostate cancer (63).
Similar findings about plasma TIMP-1 were also re-
ported in prostate cancer (64, 65). In colon cancer,
immunohistochemical detection of interstitial collagenase
is associated with a poor prognosis (66). Matrilysin
expression, measured using reverse transcriptase
polymerase chain reaction (RT-PCR), has also been
suggested to have prognostic value in colon and esopha-
geal cancer (67). In a study of esophageal carcinoma,
patients with tumors that demonstrated nomatrilysin
expression had a better disease-free and overall sur-
vival (68).
(2) The role of MMPs and TIMPs in tumor pro-
gression
The increased expression of MMPs in advanced
tumors and the ability of these enzymes to degrade
extracellular matrix barriers suggested that these
enzymes have important roles in tumor invasion
and metastasis (9, 10, 27). This hypothesis was sup-
ported by the findings from experimental and spon-
taneous metastasis models (69). Recombinant TIMP-1
decreased the number of lung nodules of B 16-F 10
melanoma cells (70). Increased establishment of lung
metastases after intravenous injection of several cancer
cells were associatedwithMMP-2,MMP-9 andMT1-MMP
(71-73). It has also been shown that MMP-2, MMP-9,
and matrilysin metastasize to appropriate target or-
gans from their primary sites in orthotopic models
of bladder, fibrosarcoma, and colon cancer (71, 72,
74). In addition, B16-F10 melanoma cells transfected
with TIMP-1 produced significantly fewer metastatic
nodules than control cells (75). These findings suggest
that MMPs and TIMPs have some roles for extravasation
to target organs from vessels. However, the role of
MMPs in tumor cell intravasation, or entry into the
vessels, appears to be better established. TIMPs have
been shown to inhibit tumor cell invasion in in vitro
invasion assay (69). Matrilysin was observed to pro-
mote invasion of DU145 prostate cells into the dia-
phragm of nude mice (76). Recently, an in vivo model
of tumor cell intravasation using the chick chorioallantoic
membrane demonstrated that the intravasation of
human epidermoid carcinoma cells was associated
with the production of MMP-9 (77). The ability of
tumor cells to penetrate the epithelial basement mem-
brane, migrate through stroma, and enter vessels
appears to be dependent onmatrix-degrading proteases,
including the MMPs. However, the process of tumor
cell invasion and metastasis is tightly coupled to
neovascularization, andMMPshave also been implicated
in the process of angiogenesis (78). Based on recent
studies withMMP-knock-outmice,MMP-2 orMMP-9
may be associated with neovascularization (79, 80).
One of the primary effects of MMPs on tumor pro-
gression also appears to be the ability to create the
space for tumor growth (19). The effect of TIMP on
the establishment of distant metastases was its ability
to inhibit the growth of tumor cells at metastatic sites
(81). In addition, MMPs also appear to contribute to
the establishment and growth of primary tumors (82-
84). Thus, MMPs appear to be able to alter the
extracellular environment and induce tumor cell es-
tablishment and growth.
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MMPs IN BLADDER CANCER
(1) Expression of MMPs in tumor tissues
In bladder cancer patients, the presence of deep
muscle invasion, infiltrative proliferation, or infiltration
to vessels is associated with a high recurrence rate
and poor prognosis (85).We evaluated the expression
of MMP-2, MMP-9 and its inhibitors TIMP-1 andTIMP-2
in 22 bladder cancer tissues by Northern blot and
slot blot analysis and High MMP-2, TIMP-1, and TIMP-2
expression levels were observed in advanced tumor
tissues (86). Davies et al. reported that MMP-2 and
MMP-9 activities quantitated by gelatin zymography
correlated with tumor grade and invasion in bladder
cancer (87). Grignon et al. showed that high levels
of TIMP-2 expression were associated with poor out-
come in bladder cancer patients undergoing radical
cystectomy (88).
We also evaluated MMP-2, TIMP-2 and MT1-MMP
expression in bladder cancer tissues using RT-PCR
analysis (89). MMP-2 and TIMP-2 expression levels
were strongly associated with tumor stage and prog-
nosis. High levels of expression ofMMP-2 and TIMP-2
were observed in muscle invasive ≧pT2 bladder can-
cer tissues compared with low stage pTa-1 tumors.
However, MT1-MMP expression was not correlated
with tumor invasion. Although, the levels ofMT1-MMP
was not associated with tumor invasion, it was asso-
ciated with patient outcome. Other studies have shown
high expression of MT1-MMP in cancer tissues and
association with invasiveness of cervical cancer cells
(90) or lymph node metastases in lung cancers (91).
Thus, there may be some tissue specificity regard-
ing the involvement of MT1-MMP in tumor invasion
or metastasis. In bladder cancer, MT1-MMP may in-
volve distant metastasis directly but not tumor in-
vasion.
The relatively activated MMP-2 expression can be
measured by gelatin zymography which is capable
of highly sensitive differentiation of latent and acti-
vated forms of gelatinases. Therefore, we determined
activation of MMP-2 using gelatin zymography (92)
(Fig. 3). The expression of activated MMP-2 and
the expression of total MMP-2 in invasive tumors
(≧pT 2) were both significantly higher than in su-
perficial tumors (pTa-1). These findings indicated that
MMP-2 expression in urothelial tumors was highly
correlated with tumor invasion, and showed a strong
correlation between the levels of activated MMP-2
and those of total MMP-2. Both expression levels were
associated in tumor invasion, but the findings sug-
gested that the activated form of MMP-2 expression
was a better indicator of tumor invasion. Moreover,
we observed that the high expression groups of the
activated form of MMP-2 and total MMP-2 showed
significantly worse cause-specific survival than did the
low expression groups. High expressions of activated
MMP-2 were more strongly linked with an unfavor-
able prognosis than was total MMP-2 expression.
We also reported MMP-2 and MT1-MMP expression
in invasive urothelial tumor tissues transplanted in
SCID mice (93).
In bladder cancer, the pathologic stage or tumor
grade is associated with patient survival. However,
even within patients of the same stage or grade, there
are some differences in patient survival (85). Therefore,
there is a need to identify other predictors for blad-
der cancer patients. We examined the survival of pa-
tients according to the levels of expression of MMP-2,
TIMP-2, and MT1-MMP to evaluate the usefulness
of these proteins as predictors. Patients with high ex-
pression levels of MMP-2, TIMP-2, or MT1-MMP
showed worse cause-specific survival, even within the
Fig. 3. Gelatin zymography of bladder cancer tissue extract. Eight urothelial cancer tissues (lanes 1 to 8) were obtained opera-
tively from the patients with bladder cancer. lane C : UCT-2 tumor line tissue extract was used as the standard in each gel. pT :
pathological stage of bladder tumor. grade : histological grade of tumor cells. 72 kilodaiton (kDa) : latent form of MMP-2. Lowest
band : activated form of MMP-2.92 kDa : latent form of MMP-9.
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group of patients with muscle invasive ≧pT2 tumors
resected radically (89). However, differences in the
MMP-2/TIMP-2 ratios did not affect survival. In our
study, the expression levels ofMMP-2was correlatedwith
those of TIMP-2. Therefore, the ratio ofMMP-2/TIMP-2
might not affect patient outcome. Grignon et al. showed that
high levels of TIMP-2, as assessed by immunohistochemical
staining, were associatedwith poor outcome in patients
with invasive bladder cancer treated by cystectomy
but that MMP-2 expression did not affect survival
(88). However, it is complicated to evaluate MMP-2
or TIMP-2 expression by immunohistochemical stain-
ing methods. Moreover, evaluation of expression by
gelatin zymography or Northern blot analysis is also
difficult to use in clinical settings. Our results dem-
onstrated that levels of MMP-2, TIMP-2, orMT1-MMP
in tumor tissues obtained by operation or biopsymay
be useful for prognosis, even in patients with muscle
invasive tumors (89, 92). It is possible that adjuvant
chemotherapy can be avoided in patients with low
levels of MMP-2 or TIMP-2 whose muscle invasive
bladder cancers have been radically resected.
Recently, several studies reportedMMP-2 andMMP-9
in bladder cancer. Papathoma et al. reported that
zymographical analysis of the levels of MMP-9 and
active MMP-2 showed a significant increase with tumor
grade and invasiveness, however, the correlation be-
tween the levels of both gelatinases with recurrence
in superficial tumors or progression in invasive tumors
was not significant (94).We evaluatedMMP-9 expres-
sion in bladder tumor tissues using gelatin zymography
(92), however, the correlation between MMP-9 expres-
sion levels and tumor invasion was weak and not
significant. The background of patients might have
been different in those two studies. Ozdemir et al .
reported a strong correlation of basement membrane
degradation with p53 inactivation and/or MDM2
overexpression in superficial urothelial carcinomas,
and they suggested that MMP-9 plays a key role in
the invasion step of superficial urothelial carcinomas
(95, 96). Kitagawa et al . reported that MT1-MMP
and MT2-MMP may play an important role in the
development and multifocal occurrence of urothelial
cancer (97).
(2) Serum MMPs and TIMPs
Recently, some studies evaluated serum levels of
MMPs and TIMPs, and their clinical usefulness. Gohji
et al. reported the prognostic significance of serum
MMPs and TIMPs, and the imbalance between serum
matrix metalloproteinase-2 and its inhibitor as a pre-
dictor of recurrence of urothelial cancer (98-100).
Measurement of plasma/serum MMP and TIMP levels
may provide important information for selecting and
following patients considered for treatment with drugs
that interfere with MMP activity (101). We also ob-
served high levels of serum TIMP-1 in patients with
advanced bladder cancers (102).
(3) Urinary MMPs and TIMPs
Moses et al. evaluated the incidence of matrix
metalloproteinases in urine of cancer patients (103).
They detected three molecular weight classes of urinary
MMPs, MMP-2, MMP-9, and high molecular weight
(Mr≧150,000) species, correlatedwith disease status.
The presence of biologically active MMP-2 or MMP-9
was an independent predictor of organ-confined cancer,
and the high molecular weight species was an inde-
pendent predictor of metastatic cancer. Monier et al.
detected 72 kDa proMMP-2 and its activated 68 kDa
form, a 92 kDa proMMP-9, and a higher molecular
weight complex (115 kDa) which was identified as
proMMP-9 (104). MMPs in urine can be used as
predictors of bladder cancer diagnosis and prognosis.
Sier et al. also reported that urinary MMP-2 and MMP-9
activity levels were significantly correlated with each
other, and they concluded that enhanced urinaryMMP
activity or especially in combination with other markers,
might be useful as a marker for superficial bladder
carcinoma (105). Detection of proMMP-9 in bladder
washes also may be a novel approach for the iden-
tification of patients with more aggressive forms of
bladder cancer (106).
(4) Regulation of MMP-2 and MMP-9 in bladder
cancer cells by cytokines
Shin et al. observed that MMP-2 and MMP-9 ex-
pression was up-regulated by tumor necrosis-alpha or
interferon-gamma, and theysuggestedBCGimmunotherapy
may enhance the invasiveness of bladder cancer in
certain conditions with induction of MMPs (107).
Kageyama et al . also suggested the possibility that
BCG promotes invasion of bladder cancer cells be-
cause of the inducedsecretionofMMP-9 fromperipheral
mononuclear cells by BCG (108). Basic fibroblast
growth factor also induces MMP-2 and MMP-9 se-
cretion from bladder cancer cells (109). However,
Slaton et al. observed interferon-alpha down regulated
the production of basic fibroblast growth factor and
MMP-9 from invasive bladder cancer cells (110). From
these findings, certain cytokines may be useful for
treatment of invasive bladder cancer by regulating
MMPs.
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CONCLUSIONS
It has been clarified that MMPs have important
roles in tumor invasion andmetastasis. Large numbers
of studies have examined the presence of individual
MMPs in different types of cancer, using various metho-
ds. In bladder cancer, although these studies sug-
gested the clinical usefulness of MMP-2 and MMP-9
in tissues, serum and urine for further diagnosis of
tumor biological activities or patient status, further
examinations of large numbers of patients are nec-
essary. In the near future, it may be possible to use
MMPs or TIMPs for clinical applications as MMPs
expression levels in biopsied cancer tissues, serum
or urine MMPs and TIMPs obtained from patients
with bladder cancer. The development of antibodies
that distinguish between pro-enzymes and activated
enzymes, and between free MMP and MMP com-
plexed with TIMP may provide new approaches for
bladder cancer diagnosis or treatment. Moreover,
MMP-2 or MMP-9 would be the target for therapy
in especially advanced bladder cancer patients. With
the development of MMP inhibitors, anti-invasion or
metastasis therapy may be useful clinically.
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